RC
XERS icon

Roundview Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Roundview Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-120,000
Closed -$977K – 352
2025
Q3 		$977K Hold
120,000
– – 0.06% 217
2025
Q2 		$560K Hold
120,000
– – 0.04% 254
2025
Q1 		$659K Hold
120,000
– – 0.05% 235
2024
Q4 		$407K Buy
+120,000
New +$386K 0.03% 282

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Roundview Capital's XERS Position: Q4 2025 in Review

Roundview Capital sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 120,000 shares — an estimated $977K sold.

Roundview Capital first reported a position in XERS in Q4 2024 and held it in 4 quarters. The position peaked at $977K in Q3 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Roundview Capital reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Roundview Capital sold 120,000 Xeris Biopharma Holdings shares in Q4 2025, an estimated $977K.
  • Roundview Capital first reported a position in Xeris Biopharma Holdings in Q4 2024 and held it in 4 quarters.
  • Roundview Capital's Xeris Biopharma Holdings position peaked at $977K in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Roundview Capital's 13F filing for Q4 2025, filed 9 Feb 2026.